Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

Background/AimsQuantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement during rescue therapy for lamivudine (LMV)-resistant CHB patients have not bee...

Full description

Bibliographic Details
Main Authors: Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2014-09-01
Series:Clinical and Molecular Hepatology
Subjects:
Hepatitis B, Chronic
Hepatitis B surface antigen
Lamivudine
Adefovir
Resistance
Online Access:http://e-cmh.org/upload/pdf/cmh-20-274.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-20-274.pdf

Similar Items